Androgen Receptor and Immune Inflammation in Benign Prostatic Hyperplasia and Prostate Cancer

Overview

Journal Clin Investig (Lond)

Date 2015 Nov 24

PMID 26594314

Citations 12

Authors

Kouji Izumi

Lei Li

Chawnshang Chang

Affiliations

Soon will be listed here.

Abstract

Both benign prostatic hyperplasia (BPH) and prostate cancer (PCa) are frequent diseases in middle-aged to elderly men worldwide. While both diseases are linked to abnormal growth of the prostate, the epidemiological and pathological features of these two prostate diseases are different. BPH nodules typically arise from the transitional zone, and, in contrast, PCa arises from the peripheral zone. Androgen deprivation therapy alone may not be sufficient to cure these two prostatic diseases due to its undesirable side effects. The alteration of androgen receptor-mediated inflammatory signals from infiltrating immune cells and prostate stromal/epithelial cells may play key roles in those unwanted events. Herein, this review will focus on the roles of androgen/androgen receptor signals in the inflammation-induced progression of BPH and PCa.

Citing Articles

Rate of castration-induced prostate stroma regression is reduced in a mouse model of benign prostatic hyperplasia.

Zhang R, Singh S, Pan C, Xu B, Kindblom J, Eng K Am J Clin Exp Urol. 2023; 11(1):12-26.

PMID: 36923722 PMC: 10009314.

Cleistanthins A and B Ameliorate Testosterone-Induced Benign Prostatic Hyperplasia in Castrated Rats by Regulating Apoptosis and Cell Differentiation.

S C S, R R, Ganesh R Cureus. 2023; 14(12):e32141.

PMID: 36601166 PMC: 9805890. DOI: 10.7759/cureus.32141.

A Role of the Heme Degradation Pathway in Shaping Prostate Inflammatory Responses and Lipid Metabolism.

Lilljebjorn L, Csizmadia E, Hedblom A, Canesin G, Kalbasi A, Li M Am J Pathol. 2020; 190(4):830-843.

PMID: 32035059 PMC: 7217330. DOI: 10.1016/j.ajpath.2019.12.008.

Suppressive Role of Androgen/Androgen Receptor Signaling via Chemokines on Prostate Cancer Cells.

Izumi K, Mizokami A J Clin Med. 2019; 8(3).

PMID: 30871130 PMC: 6463189. DOI: 10.3390/jcm8030354.

Optimal sequencing strategy using docetaxel and androgen receptor axis-targeted agents in patients with castration-resistant prostate cancer: utilization of neutrophil-to-lymphocyte ratio.

Koo K, Lee J, Ha J, Han K, Lee K, Hah Y World J Urol. 2019; 37(11):2375-2384.

PMID: 30734074 DOI: 10.1007/s00345-019-02658-1.

References

Abrams P, Schulman C, VAAGE S . Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH). The European Tamsulosin Study Group. Br J Urol. 1995; 76(3):325-36. DOI: 10.1111/j.1464-410x.1995.tb07709.x. View

Steiner G, Newman M, Paikl D, Stix U, Memaran-Dagda N, Lee C . Expression and function of pro-inflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate. 2003; 56(3):171-82. DOI: 10.1002/pros.10238. View

Rick F, Schally A, Block N, Halmos G, Perez R, Fernandez J . LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia. Prostate. 2010; 71(7):736-47. DOI: 10.1002/pros.21289. View

PERTSCHUK L, Macchia R, Feldman J, Brady K, Levine M, Kim D . Immunocytochemical assay for androgen receptors in prostate cancer: a prospective study of 63 cases with long-term follow-up. Ann Surg Oncol. 1994; 1(6):495-503. DOI: 10.1007/BF02303615. View

Horton R, Hsieh P, Barberia J, Pages L, Cosgrove M . Altered blood androgens in elderly men with prostate hyperplasia. J Clin Endocrinol Metab. 1975; 41(4):793-6. DOI: 10.1210/jcem-41-4-793. View

Shirakawa T, Okada H, Acharya B, Zhang Z, Hinata N, Wada Y . Messenger RNA levels and enzyme activities of 5 alpha-reductase types 1 and 2 in human benign prostatic hyperplasia (BPH) tissue. Prostate. 2003; 58(1):33-40. DOI: 10.1002/pros.10313. View

Mostaghel E, Geng L, Holcomb I, Coleman I, Lucas J, True L . Variability in the androgen response of prostate epithelium to 5alpha-reductase inhibition: implications for prostate cancer chemoprevention. Cancer Res. 2010; 70(4):1286-95. PMC: 2822890. DOI: 10.1158/0008-5472.CAN-09-2509. View

White J . I. The Results of Double Castration in Hypertrophy of the Prostate. Ann Surg. 1895; 22(1):1-80. PMC: 1424827. DOI: 10.1097/00000658-189507000-00001. View

Huggins C, Hodges C . Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 1972; 22(4):232-40. DOI: 10.3322/canjclin.22.4.232. View

10.

Kapoor A . Benign prostatic hyperplasia (BPH) management in the primary care setting. Can J Urol. 2012; 19 Suppl 1:10-7. View

11.

GROSSMANN M, Huang H, Tindall D . Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst. 2001; 93(22):1687-97. DOI: 10.1093/jnci/93.22.1687. View

12.

Tilley W, Buchanan G, Hickey T, Bentel J . Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clin Cancer Res. 1996; 2(2):277-85. View

13.

Culig Z, Hobisch A, Bartsch G, Klocker H . Androgen receptor--an update of mechanisms of action in prostate cancer. Urol Res. 2000; 28(4):211-9. DOI: 10.1007/s002400000111. View

14.

Izumi K, Fang L, Mizokami A, Namiki M, Li L, Lin W . Targeting the androgen receptor with siRNA promotes prostate cancer metastasis through enhanced macrophage recruitment via CCL2/CCR2-induced STAT3 activation. EMBO Mol Med. 2013; 5(9):1383-401. PMC: 3799493. DOI: 10.1002/emmm.201202367. View

15.

Wu Z, Yuan Y, Geng H, Xia S . Influence of immune inflammation on androgen receptor expression in benign prostatic hyperplasia tissue. Asian J Androl. 2011; 14(2):316-9. PMC: 3735085. DOI: 10.1038/aja.2011.154. View

16.

Craig M, Ying C, Loberg R . Co-inoculation of prostate cancer cells with U937 enhances tumor growth and angiogenesis in vivo. J Cell Biochem. 2007; 103(1):1-8. DOI: 10.1002/jcb.21379. View

17.

Tannock I, de Wit R, Berry W, Horti J, Pluzanska A, Chi K . Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 351(15):1502-12. DOI: 10.1056/NEJMoa040720. View

18.

Marks L, Partin A, Gormley G, Dorey F, Shery E, Garris J . Prostate tissue composition and response to finasteride in men with symptomatic benign prostatic hyperplasia. J Urol. 1997; 157(6):2171-8. View

19.

Izumi K, Mizokami A, Lin W, Lai K, Chang C . Androgen receptor roles in the development of benign prostate hyperplasia. Am J Pathol. 2013; 182(6):1942-9. PMC: 3668026. DOI: 10.1016/j.ajpath.2013.02.028. View

20.

Chang H, Nuyten D, Sneddon J, Hastie T, Tibshirani R, Sorlie T . Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A. 2005; 102(10):3738-43. PMC: 548329. DOI: 10.1073/pnas.0409462102. View